(Albany, US) On November 11, 2026, DelveInsight’s “Retinal Vein Occlusion Market Insights, Epidemiology and Market Forecast – 2036” report provides comprehensive insights into the Retinal Vein Occlusion (RVO) market and pipeline landscape across the 7MM. It covers marketed and emerging drug profiles and examines the epidemiology, treatment landscape, market drivers and barriers, and competitive dynamics shaping the space.
Discover the latest drugs and treatment options in the Retinal Vein Occlusion Market @ https://www.delveinsight.com/report-store/retinal-vein-occlusion-market
Key Takeaways from the Retinal Vein Occlusion Report
In the 7MM, total RVO prevalent cases were approximately 2.9 million in 2025. The US accounted for about 57%, EU4 and the UK for nearly 30%, and Japan for about 13%. Cases are expected to increase by 2036.
Gender-specific diagnosed prevalent cases were higher in females than males across the 7MM in 2025.
In EU4 and the UK, age-specific diagnosed prevalent cases in 2025 were approximately 0.10 million (
Japan accounted for approximately 0.38 million prevalent cases in 2025, predominantly Branch Retinal Vein Occlusion (BRVO), with about 0.15 million BRVO and 0.04 million Central Retinal Vein Occlusion (CRVO) diagnosed cases.
In March 2026, Kodiak Sciences announced positive topline results from GLOW2, its second Phase III study in diabetic retinopathy, demonstrating superiority of tarcocimab tedromer. The company plans to submit a single Biologics License Application in 2026 across three retinal diseases, including RVO, with an RVO launch expected in 2027.
In February 2025, Annexin Pharmaceuticals completed analysis of its Phase IIa study of ANXV in RVO, which showed promising efficacy and a strong safety profile, with biomarker reductions confirming its mechanism.
In July 2024, the US FDA granted approval for VABYSMO PFS to treat RVO. In December 2024, Roche reported that the European Medicines Agency authorized faricimab 6.0 mg in a single-dose prefilled syringe for macular edema resulting from RVO.
DelveInsight’s report depicts a market where innovation is shifting toward longer-acting anti-VEGF agents and mechanism-diverse vascular-protective therapies.
Leading Retinal Vein Occlusion companies include Roche, Kodiak, Outlook Therapeutics, Annexin Pharmaceuticals, Wakamoto Pharmaceutical, and others.
Promising therapies include faricimab (VABYSMO), triamcinolone acetonide (MaQaid), tarcocimab tedromer (KSI-301), LYTENAVA (ONS-5010), ANXV, and others.
Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Retinal Vein Occlusion Treatment Drugs
Retinal Vein Occlusion Overview
RVO is a common retinal vascular disorder characterized by partial or complete obstruction of the retinal venous circulation, leading to impaired blood flow, hemorrhage, ischemia, and macular edema. It is the second most common retinal vascular disorder after diabetic retinopathy and is classified into Central (CRVO), Branch (BRVO), and Hemiretinal (HRVO) vein occlusion based on the location of the blockage. It primarily affects adults aged 65 and above and is strongly associated with hypertension, diabetes mellitus, hyperlipidemia, atherosclerosis, glaucoma, and cardiovascular disease. Untreated RVO can lead to persistent macular edema, retinal neovascularization, vitreous hemorrhage, and irreversible vision loss.
Diagnosis relies on comprehensive ophthalmic examination supported by retinal imaging, particularly optical coherence tomography (OCT) for assessing macular edema and fluorescein angiography (FA) for evaluating ischemia, vascular occlusion, and neovascularization.
Treatment focuses on restoring and preserving vision by reducing macular edema, preventing neovascular complications, and managing systemic risk factors. Intravitreal anti-VEGF therapy remains the standard of care, with faricimab (VABYSMO), aflibercept (EYLEA), and ranibizumab (LUCENTIS). Intravitreal corticosteroids, including the dexamethasone implant (OZURDEX), are used in selected patients with inadequate response or contraindications to anti-VEGF therapy.
Retinal Vein Occlusion Emerging Drugs Profile
Tarcocimab Tedromer (KSI-301): Kodiak Sciences Tarcocimab tedromer is an intravitreal anti-VEGF biologic built on the Antibody Biopolymer Conjugate (ABC) Platform, which combines an anti-VEGF antibody with a phosphorylcholine-based biopolymer to extend drug retention in ocular tissues. Currently, the drug is in Phase III for RVO-associated macular edema, with an anticipated US launch in 2027. In September 2023, Kodiak shared one-year (48-week) top-line results from the pivotal BEACON study in patients with macular edema resulting from RVO.
LYTENAVA (ONS-5010): Outlook Therapeutics LYTENAVA is an investigational intravitreal formulation of bevacizumab developed specifically for ophthalmic use. Outlook Therapeutics has completed a Phase III study assessing the safety of ophthalmic bevacizumab in patients with branch RVO and is conducting another Phase III trial comparing vial versus prefilled syringe administration.
ANXV: Annexin Pharmaceuticals ANXV is an investigational biologic based on recombinant human Annexin A5, designed to protect retinal vasculature, stabilize endothelial cells, and reduce ischemia-induced vascular injury. In August 2024, Annexin reported positive topline Phase IIa results in RVO, showing safety and clinical benefit in most patients with limited anti-VEGF use. Currently, the drug is in Phase II.
Explore groundbreaking therapies and clinical trials in the Retinal Vein Occlusion Market @ Retinal Vein Occlusion Treatment Drugs
Retinal Vein Occlusion Market Drivers
Growing disease burden and improved diagnosis: An aging population and rising hypertension, diabetes, and hyperlipidemia, together with wider access to OCT imaging, are expanding the treatable population.
Demand for longer-acting therapies: The burden of frequent injections is driving development of durable anti-VEGF agents and novel vascular-protective therapies.
Robust late-stage pipeline: Tarcocimab tedromer, ONS-5010, and ANXV aim to extend durability and reduce injection frequency.
Recent approvals: The VABYSMO prefilled syringe approvals in the US and Europe expand options in RVO.
Mechanism diversity: Therapies beyond VEGF inhibition could complement existing treatment strategies.
Pipeline-driven innovation: Sustained-delivery platforms and new mechanisms are expected to reshape the treatment landscape.
Retinal Vein Occlusion Market Barriers
Treatment burden and poor adherence: Frequent intravitreal injections limit real-world outcomes.
Incomplete response to anti-VEGF therapy: Some patients experience persistent or recurrent macular edema.
Limited options for ischemic RVO: The risk of neovascularization and irreversible vision loss remains high.
Established standard of care: Physician familiarity with current anti-VEGF therapies may moderate early adoption of new agents.
Limited differentiated pipeline: Only a small number of investigational therapies are in development.
Learn about new drugs, pipeline developments, and key players with DelveInsight’s expert analysis @ Retinal Vein Occlusion Market Drivers and Barriers
Scope of the Retinal Vein Occlusion Report
Coverage: 7MM (US, EU4, UK, Japan)
Companies: Roche, Kodiak, Outlook Therapeutics, Annexin Pharmaceuticals, Wakamoto Pharmaceutical, and others
Therapies: Faricimab (VABYSMO), triamcinolone acetonide (MaQaid), tarcocimab tedromer (KSI-301), LYTENAVA (ONS-5010), ANXV, and others
Study Period: 2022–2036 (Historical: 2022–2025; Forecast: 2026–2036; Base Year: 2026)
Analysis: Epidemiology segmentation, addressable patient population, market size by therapy, cost assumptions and pricing analogues, drug uptake, KOL views, SWOT, conjoint analysis, reimbursement, unmet needs
Download DelveInsight’s in-depth Retinal Vein Occlusion report today! @ Retinal Vein Occlusion Companies
Table of Contents
Introduction
Executive Summary
Retinal Vein Occlusion: Overview
Epidemiology and Patient Burden
Current Treatment Practices
Marketed Therapies
Emerging Therapies
Key Companies
Market Outlook
Drug Uptake
Market Access and Reimbursement
Pricing and Analogue Assessment
KOL Views
SWOT and Conjoint Analysis
Unmet Needs
Market Drivers and Barriers
Appendix
About Us
About DelveInsight
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and infrastructure to clients across the globe.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Mehul MalhotraEmail: Send EmailPhone: 09650213330Address:A-1 NV 89107City: delhiState: IndianaCountry: United StatesWebsite: https://www.delveinsight.com/consulting
